An overview of the role of selpercatinib and pralsetinib in RET-fusion-positive non-small cell lung cancer (NSCLC).

Vanessa Quang NguyenMarc Geirnaert

Published in: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (2022)

Overall, the increased use of selpercatinib and pralsetinib has led to the implementation of these drugs in the clinical practice of healthcare professionals such as pharmacists.

Keyphrases

clinical practice
small cell lung cancer
primary care
healthcare
advanced non small cell lung cancer
quality improvement
general practice
brain metastases
drug induced
light emitting
epidermal growth factor receptor
tyrosine kinase